HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schock, H. B. Articles by Kuo, L. C. Search for Related Content PubMed PubMed Citation Articles by Schock, H. B. Articles by Kuo, L. C. Social Bookmarking                      What's this?

Volume 271, Number 50, Issue of December 13, 1996 pp. 31957-31963
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Mutational Anatomy of an HIV-1 Protease Variant Conferring Cross-resistance to Protease Inhibitors in Clinical Trials
COMPENSATORY MODULATIONS OF BINDING AND ACTIVITY

(Received for publication, May 20, 1996, and in revised form, September 16, 1996)

From the Department of Antiviral Research, Merck Research Laboratories, West Point, Pennsylvania 19486

Site-specific substitutions of as few as four amino acids (M46I/L63P/V82T/I84V) of the human immunodeficiency virus type 1 (HIV-1) protease engenders cross-resistance to a panel of protease inhibitors that are either in clinical trials or have recently been approved for HIV therapy (Condra, J. H., Schleif, W. A., Blahy, O. M., Gadryelski, L. J., Graham, D. J., Quintero, J. C., Rhodes, A., Robbins, H. L., Roth, E., Shivaprakash, M., Titus, D., Yang, T., Teppler, H., Squires, K. E., Deutsch, P. J., and Emini, E. A. (1995) Nature 374, 569-571). These four substitutions are among the prominent mutations found in primary HIV isolates obtained from patients undergoing therapy with several protease inhibitors. Two of these mutations (V82T/I84V) are located in, while the other two (M46I/L63P) are away from, the binding cleft of the enzyme. The functional role of these mutations has now been delineated in terms of their influence on the binding affinity and catalytic efficiency of the protease. We have found that the double substitutions of M46I and L63P do not affect binding but instead endow the enzyme with a catalytic efficiency significantly exceeding (110-360%) that of the wild-type enzyme. In contrast, the double substitutions of V82T and I84V are detrimental to the ability of the protease to bind and, thereby, to catalyze. When combined, the four amino acid replacements institute in the protease resistance against inhibitors and a significantly higher catalytic activity than one containing only mutations in its active site. The results suggest that in raising drug resistance, these four site-specific mutations of the protease are compensatory in function; those in the active site diminish equilibrium binding (by increasing K_i), and those away from the active site enhance catalysis (by increasing k_cat/K_M). This conclusion is further supported by energy estimates in that the Gibbs free energies of binding and catalysis for the quadruple mutant are quantitatively dictated by those of the double mutants.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Dykes and L. M. Demeter Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness Clin. Microbiol. Rev., October 1, 2007; 20(4): 550 - 578. [Abstract] [Full Text] [PDF]

				S. Weinheimer, L. Discotto, J. Friborg, H. Yang, and R. Colonno Atazanavir Signature I50L Resistance Substitution Accounts for Unique Phenotype of Increased Susceptibility to Other Protease Inhibitors in a Variety of Human Immunodeficiency Virus Type 1 Genetic Backbones Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3816 - 3824. [Abstract] [Full Text] [PDF]

				W. Resch, N. Parkin, T. Watkins, J. Harris, and R. Swanstrom Evolution of Human Immunodeficiency Virus Type 1 Protease Genotypes and Phenotypes In Vivo under Selective Pressure of the Protease Inhibitor Ritonavir J. Virol., August 15, 2005; 79(16): 10638 - 10649. [Abstract] [Full Text] [PDF]

				N. M. King, M. Prabu-Jeyabalan, E. A. Nalivaika, P. Wigerinck, M.-P. de Bethune, and C. A. Schiffer Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor J. Virol., November 1, 2004; 78(21): 12012 - 12021. [Abstract] [Full Text] [PDF]

				S. Tamiya, S. Mardy, M. F. Kavlick, K. Yoshimura, and H. Mistuya Amino Acid Insertions near Gag Cleavage Sites Restore the Otherwise Compromised Replication of Human Immunodeficiency Virus Type 1 Variants Resistant to Protease Inhibitors J. Virol., November 1, 2004; 78(21): 12030 - 12040. [Abstract] [Full Text] [PDF]

				R. A. K. Singh and M. A. Barry Repertoire and Immunofocusing of CD8 T Cell Responses Generated by HIV-1 gag-pol and Expression Library Immunization Vaccines J. Immunol., October 1, 2004; 173(7): 4387 - 4393. [Abstract] [Full Text] [PDF]

				A. A. Nabatov, G. Pollakis, T. Linnemann, A. Kliphius, M. I. M. Chalaby, and W. A. Paxton Intrapatient Alterations in the Human Immunodeficiency Virus Type 1 gp120 V1V2 and V3 Regions Differentially Modulate Coreceptor Usage, Virus Inhibition by CC/CXC Chemokines, Soluble CD4, and the b12 and 2G12 Monoclonal Antibodies J. Virol., January 1, 2004; 78(1): 524 - 530. [Abstract] [Full Text] [PDF]

				T. D. Wu, C. A. Schiffer, M. J. Gonzales, J. Taylor, R. Kantor, S. Chou, D. Israelski, A. R. Zolopa, W. J. Fessel, and R. W. Shafer Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments J. Virol., April 15, 2003; 77(8): 4836 - 4847. [Abstract] [Full Text] [PDF]

				T. Watkins, W. Resch, D. Irlbeck, and R. Swanstrom Selection of High-Level Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors Antimicrob. Agents Chemother., February 1, 2003; 47(2): 759 - 769. [Abstract] [Full Text] [PDF]

				M. Prabu-Jeyabalan, E. A. Nalivaika, N. M. King, and C. A. Schiffer Viability of a Drug-Resistant Human Immunodeficiency Virus Type 1 Protease Variant: Structural Insights for Better Antiviral Therapy J. Virol., December 20, 2002; 77(2): 1306 - 1315. [Abstract] [Full Text] [PDF]

				W. Resch, R. Ziermann, N. Parkin, A. Gamarnik, and R. Swanstrom Nelfinavir-Resistant, Amprenavir-Hypersusceptible Strains of Human Immunodeficiency Virus Type 1 Carrying an N88S Mutation in Protease Have Reduced Infectivity, Reduced Replication Capacity, and Reduced Fitness and Process the Gag Polyprotein Precursor Aberrantly J. Virol., July 29, 2002; 76(17): 8659 - 8666. [Abstract] [Full Text] [PDF]

				E.-Y. Kim, M. A. Winters, R. M. Kagan, and T. C. Merigan Functional Correlates of Insertion Mutations in the Protease Gene of Human Immunodeficiency Virus Type 1 Isolates from Patients J. Virol., November 15, 2001; 75(22): 11227 - 11233. [Abstract] [Full Text] [PDF]

				B. Buhler, Y.-C. Lin, G. Morris, A. J. Olson, C.-H. Wong, D. D. Richman, J. H. Elder, and B. E. Torbett Viral Evolution in Response to the Broad-Based Retroviral Protease Inhibitor TL-3 J. Virol., October 1, 2001; 75(19): 9502 - 9508. [Abstract] [Full Text] [PDF]

				D. J. Kempf, J. D. Isaacson, M. S. King, S. C. Brun, Y. Xu, K. Real, B. M. Bernstein, A. J. Japour, E. Sun, and R. A. Rode Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients J. Virol., August 15, 2001; 75(16): 7462 - 7469. [Abstract] [Full Text] [PDF]

				G. Bleiber, M. Munoz, A. Ciuffi, P. Meylan, and A. Telenti Individual Contributions of Mutant Protease and Reverse Transcriptase to Viral Infectivity, Replication, and Protein Maturation of Antiretroviral Drug-Resistant Human Immunodeficiency Virus Type 1 J. Virol., April 1, 2001; 75(7): 3291 - 3300. [Abstract] [Full Text]

				A. D. Kelleher, C. Long, E. C. Holmes, R. L. Allen, J. Wilson, C. Conlon, C. Workman, S. Shaunak, K. Olson, P. Goulder, et al. Clustered Mutations in HIV-1 gag Are Consistently Required for Escape from HLA-B27-restricted Cytotoxic T Lymphocyte Responses J. Exp. Med., February 5, 2001; 193(3): 375 - 386. [Abstract] [Full Text] [PDF]

				J. G. Bishop, A. M. Dean, and T. Mitchell-Olds Rapid evolution in plant chitinases: Molecular targets of selection in plant-pathogen coevolution PNAS, May 9, 2000; 97(10): 5322 - 5327. [Abstract] [Full Text] [PDF]

				D. B. Olsen, M. W. Stahlhut, C. A. Rutkowski, H. B. Schock, A. L. vanOlden, and L. C. Kuo Non-active Site Changes Elicit Broad-based Cross-resistance of the HIV-1 Protease to Inhibitors J. Biol. Chem., August 20, 1999; 274(34): 23699 - 23701. [Abstract] [Full Text] [PDF]

				J. Martinez-Picado, A. V. Savara, L. Sutton, and R. T. D'Aquila Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1 J. Virol., May 1, 1999; 73(5): 3744 - 3752. [Abstract] [Full Text]

				C. D. Rosin, R. K. Belew, G. M. Morris, A. J. Olson, and D. S. Goodsell Coevolutionary analysis of resistance-evading peptidomimetic inhibitors of HIV-1 protease PNAS, February 16, 1999; 96(4): 1369 - 1374. [Abstract] [Full Text] [PDF]

				R. Arakaki, H. Tamamura, M. Premanathan, K. Kanbara, S. Ramanan, K. Mochizuki, M. Baba, N. Fujii, and H. Nakashima T134, a Small-Molecule CXCR4 Inhibitor, Has No Cross-Drug Resistance with AMD3100, a CXCR4 Antagonist with a Different Structure J. Virol., February 1, 1999; 73(2): 1719 - 1723. [Abstract] [Full Text]

				L. Melnick, S.-S. Yang, R. Rossi, C. Zepp, and D. Heefner An Escherichia coli Expression Assay and Screen for Human Immunodeficiency Virus Protease Variants with Decreased Susceptibility to Indinavir Antimicrob. Agents Chemother., December 1, 1998; 42(12): 3256 - 3265. [Abstract] [Full Text]

				D. Boden and M. Markowitz Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors Antimicrob. Agents Chemother., November 1, 1998; 42(11): 2775 - 2783. [Full Text]

				A. K. Patick, M. Duran, Y. Cao, D. Shugarts, M. R. Keller, E. Mazabel, M. Knowles, S. Chapman, D. R. Kuritzkes, and M. Markowitz Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir Antimicrob. Agents Chemother., October 1, 1998; 42(10): 2637 - 2644. [Abstract] [Full Text]

				A. Carrillo, K. D. Stewart, H. L. Sham, D. W. Norbeck, W. E. Kohlbrenner, J. M. Leonard, D. J. Kempf, and A. Molla In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to ABT-378, a Novel Protease Inhibitor J. Virol., September 1, 1998; 72(9): 7532 - 7541. [Abstract] [Full Text] [PDF]

				M. S. Hirsch, B. Conway, R. T. D'Aquila, V. A. Johnson, F. Brun-Vezinet, B. Clotet, L. M. Demeter, S. M. Hammer, D. M. Jacobsen, D. R. Kuritzkes, et al. Antiretroviral Drug Resistance Testing in Adults With HIV Infection: Implications for Clinical Management JAMA, June 24, 1998; 279(24): 1984 - 1991. [Abstract] [Full Text] [PDF]

				H. J. Sices and T. M. Kristie A genetic screen for the isolation and characterization of site-specific proteases PNAS, March 17, 1998; 95(6): 2828 - 2833. [Abstract] [Full Text] [PDF]